CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
0.730
-0.035 (-4.60%)
At close: Dec 20, 2024, 4:00 PM
0.720
-0.010 (-1.33%)
After-hours: Dec 20, 2024, 7:54 PM EST
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
46.57M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 81.50M |
| SHL Telemedicine | 55.94M |
| iCAD, Inc. | 18.94M |
| Omega Therapeutics | 8.10M |
| Nutriband | 2.02M |
| vTv Therapeutics | 1.00M |
| Inovio Pharmaceuticals | 203.41K |
CVM News
- 9 days ago - CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study - Business Wire
- 6 weeks ago - Stock Picks From Seeking Alpha's October 2024 New Analysts - Seeking Alpha
- 6 weeks ago - U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025 - Business Wire
- 2 months ago - FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients - Business Wire
- 2 months ago - CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer - Business Wire
- 3 months ago - CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation - Business Wire
- 3 months ago - CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress - Business Wire
- 3 months ago - The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance - Business Wire